Increasing AR by HIF-2α inhibitor (PT-2385) overcomes the side-effects of sorafenib by suppressing hepatocellular carcinoma invasion via alteration of pSTAT3, pAKT and pERK signals

Junjie Xu(Kunming University of Science and Technology), Xiujun Cai(National Instruments (Ireland))
Cell Death and Disease
October 12, 2017
Cited by 73


Related Papers